Blockage of Wnt/β‐Catenin Signaling by Nanoparticles Reduces Survival and Proliferation of CLL Cells In Vitro—Preliminary Study
Source abstract
Abstract
Abstract The Wnt/β‐catenin signaling pathway is shown to play a significant role in the control of the survival, proliferation, and differentiation of hematopoietic cells. Studies have confirmed that aberrant activation of canonical Wnt signaling occurs in various forms of leukemia, and is crucial for chronic lymphocytic leukemia (CLL) pathogenesis. The aim of the study is to evaluate the influence of maltotriose (M3) modified fourth generation poly(propylene imine) dendrimers (PPI‐G4) on Wnt/β‐catenin pathway gene expression in CLL (MEC‐1) cells and to compare these findings with those obtained with fludarabine (FA). Microarray data analysis reveals seven of 19 Wnt/β‐catenin pathway genes whose expression changes significantly during dendrimer and FA treatment: WNT10A, WNT6, and CDH1 among others. PPI‐G4‐M3 is already known to influence MEC‐1 cell apoptosis and proliferation. The obtained results suggest that the reduction in cell survival under the influence of glycodendrimers and FA may be due to loss of Wnt signaling.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Chronic Lymphocytic Leukemia Research · Wnt/β-catenin signaling in development and cancer · Chronic Myeloid Leukemia Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Clinical and Laboratory Genetics Medical University of Lodz Pomorska Str. 251 92‐213 Lodz Poland
Laboratory of Clinical and Transplant Immunology and Genetics Copernicus Memorial Hospital Pabianicka Str. 62 93‐513 Lodz Poland
GeneaMed LTD Kopcinskiego Str. 16/18/904 90‐232 Lodz Poland
Department of Computer Engineering Wroclaw University of Technology Janiszewskiego Str. 11/17 50‐372 Wroclaw Poland
Leibniz Institute of Polymer Research Dresden Hohe Str. 6 D‐01069 Dresden Germany
Department of Hematology Medical University of Lodz Copernicus Memorial Hospital Pabianicka Str. 62 93‐513 Lodz Poland
Department of General Biophysics Faculty of Biology and Environmental Protection University of Lodz Pomorska Str. 141/143 90‐236 Lodz Poland
Funding
Narodowe Centrum Nauki · Uniwersytet Łódzki
References (61)
Show source-provided references
1. Caligaris‐Cappio F. · Blood Cells · 1993 · 19 · 601
2. 10.1016/j.cellsig.2012.03.00810.1016/j.cellsig.2012.03.008 ↗
3. 10.1182/blood.V97.9.277710.1182/blood.V97.9.2777 ↗
4. 10.1172/JCI2340910.1172/JCI23409 ↗
5. 10.1056/NEJMra04172010.1056/NEJMra041720 ↗
6. 10.18632/oncotarget.1355710.18632/oncotarget.13557 ↗
7. Burger J. A. · Blood · 2000 · 96 · 265510.1182/blood.V96.8.2655 ↗
8. 10.1084/jem.194.11.163910.1084/jem.194.11.1639 ↗
9. 10.1146/annurev.cellbio.20.010403.11312610.1146/annurev.cellbio.20.010403.113126 ↗
10. 10.1038/leu.2011.38710.1038/leu.2011.387 ↗
11. 10.1016/j.stem.2008.12.00410.1016/j.stem.2008.12.004 ↗
12. 10.3390/cancers809007810.3390/cancers8090078 ↗
13. 10.1016/j.imbio.2014.09.00110.1016/j.imbio.2014.09.001 ↗
14. 10.1038/nsmb91210.1038/nsmb912 ↗
15. 10.1007/s13277-016-5039-510.1007/s13277-016-5039-5 ↗
16. 10.1182/blood-2014-10-60603810.1182/blood-2014-10-606038 ↗
17. b)Safety of PCI‐32765 in Chronic Lymphocytic Leukemia www://clinicaltrials.gov/ct2/show/results/NCT01105247(accessed:February 2014).
18. O'Brien S. M. · 2016
19. b)C. I.Amaya‐Chanaga M. Y.Choi N.Nguyen E.DeVore C.MacCarthy J.Hilger‐Rolfe T. J.Kipps J. E.Castro presented at58th ASH Conf. San Diego CA December2016.
20. 10.1295/polymj.17.11710.1295/polymj.17.117 ↗
21. 10.1021/acs.bioconjchem.5b0056810.1021/acs.bioconjchem.5b00568 ↗
22. 10.3109/1061186X.2015.107785010.3109/1061186X.2015.1077850 ↗
23. 10.3109/1061186X.2013.77177810.3109/1061186X.2013.771778 ↗
24. 10.1007/s10867-012-9277-510.1007/s10867-012-9277-5 ↗
25. Soltani F. · Artif. Cells, Nanomed., Biotechnol. · 2016 · 31 · 1
26. 10.1016/j.colsurfb.2013.03.04510.1016/j.colsurfb.2013.03.045 ↗
27. 10.1016/j.nano.2016.11.01010.1016/j.nano.2016.11.010 ↗
28. 10.1016/j.drudis.2016.09.01310.1016/j.drudis.2016.09.013 ↗
29. 10.1016/j.ijpharm.2013.12.01110.1016/j.ijpharm.2013.12.011 ↗
30. 10.1021/mp400142p10.1021/mp400142p ↗
31. Franiak‐Pietryga I. · Anticancer Agents Med. Chem. · 2017 · 17 · 10210.2174/1871520616666160622092947 ↗
32. 10.1002/anie.19931308110.1002/anie.199313081 ↗
33. 10.1002/bip.2205610.1002/bip.22056 ↗
34. 10.1002/jbm.a.3422210.1002/jbm.a.34222 ↗
35. 10.1002/jbm.a.3319610.1002/jbm.a.33196 ↗
36. 10.1002/jbio.20091000210.1002/jbio.200910002 ↗
37. 10.1098/rspa.2009.010710.1098/rspa.2009.0107 ↗
38. Franiak‐Pietryga I. · Blood · 2012 · 120 · 460110.1182/blood.V120.21.4601.4601 ↗
39. Zaborowska A. · Acta Hematol. Pol. · 2009 · 40 · 887
40. 10.5604/17322693.101503610.5604/17322693.1015036 ↗
41. 10.1080/104281903100009020010.1080/1042819031000090200 ↗
42. 10.1016/S0145-2126(98)00154-410.1016/S0145-2126(98)00154-4 ↗
43. 10.2202/1544-6115.102710.2202/1544-6115.1027 ↗
44. 10.1111/j.1467-9868.2006.00551.x10.1111/j.1467-9868.2006.00551.x ↗
45. 10.1039/C4CS00339J10.1039/C4CS00339J ↗
46. 10.1016/j.ijpharm.2016.09.06310.1016/j.ijpharm.2016.09.063 ↗
47. Jelinek D. F. · Mol. Cancer Res. · 2003 · 1 · 346
48. 10.1073/pnas.030864810010.1073/pnas.0308648100 ↗
49. 10.1038/nri236010.1038/nri2360 ↗
50. Kirikoshi H. · Int. J. Oncol. · 2001 · 19 · 533
51. 10.1182/blood-2008-06-16330310.1182/blood-2008-06-163303 ↗
52. 10.1242/jcs.0062310.1242/jcs.00623 ↗
53. 10.1038/nri152910.1038/nri1529 ↗
54. 10.1038/nature75610.1038/nature756 ↗
55. 10.1074/jbc.M60027420010.1074/jbc.M600274200 ↗
56. 10.1126/science.109429110.1126/science.1094291 ↗
57. 10.1182/blood-2009-03-20648210.1182/blood-2009-03-206482 ↗
58. 10.1182/blood-2010-02-26987810.1182/blood-2010-02-269878 ↗
59. 10.1593/neo.9197210.1593/neo.91972 ↗
60. 10.1371/journal.pone.000829410.1371/journal.pone.0008294 ↗
61. 10.1016/j.addr.2013.09.01910.1016/j.addr.2013.09.019 ↗